JP2018030860A - 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 - Google Patents
成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 Download PDFInfo
- Publication number
- JP2018030860A JP2018030860A JP2017179578A JP2017179578A JP2018030860A JP 2018030860 A JP2018030860 A JP 2018030860A JP 2017179578 A JP2017179578 A JP 2017179578A JP 2017179578 A JP2017179578 A JP 2017179578A JP 2018030860 A JP2018030860 A JP 2018030860A
- Authority
- JP
- Japan
- Prior art keywords
- mood
- dietary supplement
- memory
- anxiety
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036651 mood Effects 0.000 title claims abstract description 57
- 230000000694 effects Effects 0.000 title description 35
- 229920001282 polysaccharide Polymers 0.000 title description 30
- 239000005017 polysaccharide Substances 0.000 title description 30
- 230000001149 cognitive effect Effects 0.000 title description 15
- 230000001154 acute effect Effects 0.000 title description 8
- 150000004676 glycans Chemical class 0.000 title description 8
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 51
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 44
- 230000036506 anxiety Effects 0.000 claims abstract description 43
- 230000019771 cognition Effects 0.000 claims abstract description 35
- 208000019914 Mental Fatigue Diseases 0.000 claims abstract description 32
- 230000013016 learning Effects 0.000 claims abstract description 27
- 230000006399 behavior Effects 0.000 claims abstract description 24
- 230000015654 memory Effects 0.000 claims description 45
- 230000006872 improvement Effects 0.000 abstract description 15
- 230000009467 reduction Effects 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000004048 modification Effects 0.000 abstract description 8
- 238000012986 modification Methods 0.000 abstract description 8
- 230000006993 memory improvement Effects 0.000 abstract description 5
- 230000003931 cognitive performance Effects 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 36
- 239000008103 glucose Substances 0.000 description 36
- 150000004804 polysaccharides Chemical class 0.000 description 36
- 150000001720 carbohydrates Chemical class 0.000 description 35
- 238000012360 testing method Methods 0.000 description 33
- 239000008280 blood Substances 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 31
- 241000196324 Embryophyta Species 0.000 description 26
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 22
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 20
- 239000000902 placebo Substances 0.000 description 17
- 229940068196 placebo Drugs 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 16
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 16
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 15
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 239000011782 vitamin Substances 0.000 description 12
- 229940088594 vitamin Drugs 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- 208000028173 post-traumatic stress disease Diseases 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 9
- 229920000189 Arabinogalactan Polymers 0.000 description 9
- 239000001904 Arabinogalactan Substances 0.000 description 9
- 235000019312 arabinogalactan Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 125000000185 sucrose group Chemical group 0.000 description 9
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 8
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 8
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 8
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 8
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 229930182830 galactose Natural products 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 7
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 7
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 7
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 229940097043 glucuronic acid Drugs 0.000 description 7
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 description 7
- 230000036642 wellbeing Effects 0.000 description 7
- 208000007848 Alcoholism Diseases 0.000 description 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 201000007930 alcohol dependence Diseases 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- 206010019196 Head injury Diseases 0.000 description 5
- 208000013200 Stress disease Diseases 0.000 description 5
- 208000029028 brain injury Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960002442 glucosamine Drugs 0.000 description 5
- 229920000591 gum Polymers 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000019899 phobic disease Diseases 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 230000003936 working memory Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 230000037007 arousal Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 239000012676 herbal extract Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000010365 information processing Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000626 neurodegenerative effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000305 astragalus gummifer gum Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000005903 Dioscorea Nutrition 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000010490 psychological well-being Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- -1 rinses Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZZNXTYCNZKDUFC-UHFFFAOYSA-N 5-hydroxy-2,8,9-trioxa-1-borabicyclo[3.3.2]decane-3,7,10-trione Chemical compound C1C(=O)OB2OC(=O)CC1(O)C(=O)O2 ZZNXTYCNZKDUFC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002283 Capsicum annuum var aviculare Nutrition 0.000 description 1
- 235000013303 Capsicum annuum var. frutescens Nutrition 0.000 description 1
- 235000002284 Capsicum baccatum var baccatum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000011952 auditory verbal learning test Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940008219 boron citrate Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 230000036992 cognitive tasks Effects 0.000 description 1
- 229940082939 cola nut extract Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000024622 response to vitamin Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
験後レベルを比較して、前記ヒト対象における前記栄養補助食品の前記投与の継続、終了又は修正を決定するステップとを含む。一態様において、ヒト対象は、1若しくは2以上の心臓病、糖尿病、頭部/脳損傷、神経学的疾患、神経変性状態、精神疾患又はそれらの任意の組合せを患っていてもよい。別の態様において、緊張又は不安は、1若しくは2以上のストレス障害、心的外傷後ストレス障害(PTSD)、恐怖症、心的外傷又はそれらの任意の組合せに起因する。さらに別の態様において、栄養補助食品は、中枢神経系作用薬によって誘発される1若しくは2以上の副作用、アルコール依存症又はそれらの任意の組合せを軽減する。
すなわち本発明は、以下のとおりである。
(1)ヒト対象における認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せのための方法であって、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せを必要とするヒト対象を特定するステップと、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せに充分な量の、栄養有効量の栄養補助食品を投与するステップと
を含む方法。
(2)栄養補助食品が、経口投与のために適合されている、上記(1)に記載の方法。
(3)栄養補助食品が粉末であるか、液体中に溶解されているか、カプセル化されているか、又はそれらの任意の組合せである、上記(1)に記載の方法。
(4)栄養補助食品の投与前にヒト対象において認知、記憶、気分、緊張若しくは不安のレベル又はそれらの任意の組合せを評価するための1又は2以上の試験を実施して、前記ヒト対象のベースラインレベル又は試験前レベルを決定するステップと、
前記栄養補助食品の投与後の1又は2以上の特定の時点で前記ヒト対象において前記認知、記憶、気分、緊張若しくは不安のレベル又はそれらの任意の組合せを評価するための1又は2以上の試験を実施して、前記ヒト対象の試験後レベルを決定するステップと、
前記ベースラインレベルと前記試験後レベルを比較して、前記ヒト対象における前記栄養補助食品の投与の継続、終了又は修正を決定するステップと
をさらに含む、上記(1)に記載の方法。
(5)ヒト対象が、1若しくは2以上の心臓病、糖尿病、頭部/脳損傷、神経学的疾患、神経変性状態、精神疾患又はそれらの任意の組合せを患っていてもよい、上記(1)に記載の方法。
(6)緊張又は不安が、1若しくは2以上のストレス障害、心的外傷後ストレス障害(PTSD)、恐怖症、心的外傷又はそれらの任意の組合せに起因する、上記(1)に記載の方法。
(7)栄養補助食品が、中枢神経系作用薬によって誘発される1若しくは2以上の副作用、アルコール依存症又はそれらの任意の組合せを軽減する、上記(1)に記載の方法。
(8)栄養補助食品の投与前及び投与後に血中グルコースレベルを測定するステップをさらに含む、上記(1)に記載の方法。
(9)栄養補助食品が、対象において血中グルコースレベルの上昇を引き起こさない、上記(1)に記載の方法。
(10)栄養補助食品を、1つの剤形又は剤形の組合せで同時に又は連続して投与し得る、上記(1)に記載の方法。
(11)栄養補助食品を、1種若しくは2種以上の薬剤、ビタミン、他の栄養補給剤又はそれらの任意の組合せと同時に又は連続して投与してもよい、上記(1)に記載の方法。
(12)栄養補助食品が、
単離・精製したアセチル化マンノースの栄養有効量と、
ガラクトース、グルコース、マンノース、キシロース、N−アセチルノイラミン酸、フコース、N−アセチルガラクトサミン、N−アセチルグルコサミン、アラビノース、グルクロン酸、ガラクツロン酸、イズロン酸及びアラビノガラクタンから選択される、少なくとも5種の単離・精製したサッカライドの栄養有効量と
を含む、上記(1)に記載の方法。
(13)血中グルコースレベルの上昇を引き起こさない、ヒト対象における、認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組み合わせのための方法であって、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せを必要とするヒト対象を特定するステップと、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せに充分な量の、栄養有効量の栄養補助食品を投与するステップと
を含む方法。
(14)栄養補助食品が、経口投与のために適合されている、上記(13)に記載の方法。
(15)栄養補助食品が粉末であるか、液体中に溶解されているか、カプセル化されているか、又はそれらの任意の組合せである、上記(13)に記載の方法。
(16)栄養補助食品の投与前及び投与後に血中グルコースレベルを測定するステップをさらに含む、上記(13)に記載の方法。
(17)血中グルコースレベルが異常に上昇した場合、栄養補助食品の投与を終了させるステップをさらに含む、上記(13)に記載の方法。
(18)栄養補助食品の投与前にヒト対象において認知、記憶、気分、緊張若しくは不安のレベル又はそれらの任意の組合せを評価するための1又は2以上の試験を実施して、前記ヒト対象のベースラインレベル又は試験前レベルを決定するステップと、
前記栄養補助食品の投与後の1又は2以上の特定の時点で前記ヒト対象において前記認知、記憶、気分、緊張若しくは不安のレベル又はそれらの任意の組合せを評価するための1又は2以上の試験を実施して、前記ヒト対象の試験後レベルを決定するステップと、
前記ベースラインレベルと前記試験後レベルを比較して、前記ヒト対象における前記栄養補助食品の投与の継続、終了又は修正を決定するステップと
をさらに含む、上記(13)に記載の方法。
(19)ヒト対象が、1若しくは2以上の心臓病、糖尿病、頭部/脳損傷、神経学的疾患、神経変性状態、精神疾患又はそれらの任意の組合せを患っていてもよい、上記(13)に記載の方法。
(20)緊張又は不安が、1若しくは2以上のストレス障害、心的外傷後ストレス障害(PTSD)、恐怖症、心的外傷又はそれらの任意の組合せに起因する、上記(13)に記載の方法。
(21)栄養補助食品が、中枢神経系作用薬によって誘発される1若しくは2以上の副作用、アルコール依存症又はそれらの任意の組合せを軽減する、上記(13)に記載の方法。
(22)栄養補助食品を、1つの剤形又は剤形の組合せで同時に又は連続して投与し得る、上記(13)に記載の方法。
(23)栄養補助食品を、1種若しくは2種以上の薬剤、ビタミン、他の栄養補給剤又はそれらの任意の組合せと同時に又は連続して投与してもよい、上記(13)に記載の方法。
(24)栄養補助食品が、
単離・精製したアセチル化マンノースの栄養有効量と、
ガラクトース、グルコース、マンノース、キシロース、N−アセチルノイラミン酸、フコース、N−アセチルガラクトサミン、N−アセチルグルコサミン、アラビノース、グルクロン酸、ガラクツロン酸、イズロン酸及びアラビノガラクタンから選択される、少なくとも5種の単離・精製したサッカライドの栄養有効量と
を含む、上記(13)に記載の方法。
(25)少なくとも5種の単離・精製したサッカライドが、グルコサミン及びラムノースをさらに含む、上記(24)に記載の方法。
(26)ヒト対象における、認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せのための方法であって、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せを必要とするヒト対象を特定するステップと、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せに充分な量の、栄養有効量の栄養補助食品を投与するステップと
を含み、前記栄養補助食品が、
単離・精製したアセチル化マンノースの栄養有効量と、
ガラクトース、グルコース、マンノース、キシロース、N−アセチルノイラミン酸、フコース、N−アセチルガラクトサミン、N−アセチルグルコサミン、アラビノース、グルクロン酸、ガラクツロン酸、イズロン酸及びアラビノガラクタンから選択される、少なくとも5種の単離・精製したサッカライドの栄養有効量と
を含む、方法。
学習及び記憶:Rey Auditory-Verbal Learning Test(RAVLT)[1]を用いて、即時想起、遅延想起、学習及び認識記憶を評価した。試験者は5回のトライアル全てにわたり、15個の名詞(リストA)を声に出して読み、各トライアル後に、任意の順序で15個の単語をできるだけ多く想起するよう参加者に求める。5回のトライアルのスコアを合計して、直接想起の評価尺度とし、トライアル5とトライアル1の差を学習の評価尺度として使用する。15個の異なる単語(リストB)からなる6回目のトライアルの後、参加者に再び、リストAに示されていた単語を想起するよう命じ(トライアル7)、次に60分の間隔を置いた後に再び同様なことを行う(トライアル8)。トライアル7及び8からのスコアを用いて、遅延想起の評価尺度を作成し、トライアル8及び7において想起された単語の差を、忘却の評価尺度として使用し、トライアル7とトライアル5との差を干渉の評価尺度として使用する。トライアル8の後に、不正解の単語20個の中にリストA及びBからの単語を含有する50個の単語のシートを参加者に示す。参加者に、リストA及びBからの単語を見分けて、それらの単語がリストA及びBのいずれに記載されていたかを示すよう求める。正しく特定された各単語に1点を与え、認知の評価尺度とする。
Claims (1)
- ヒト対象における認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せのための方法であって、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せを必要とするヒト対象を特定するステップと、
認知の改善、気分の改善、学習の改善、記憶の改善、緊張の低減、不安の低減、精神的疲労の低減、行動の修正、又はそれらの任意の組合せに充分な量の、栄養有効量の栄養補助食品を投与するステップと
を含む方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020070727A JP7311114B2 (ja) | 2011-04-27 | 2020-04-10 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161479632P | 2011-04-27 | 2011-04-27 | |
US61/479,632 | 2011-04-27 | ||
US13/453,540 US20120276208A1 (en) | 2011-04-27 | 2012-04-23 | Acute cognitive and mood effects of plant polysaccharides in adult human subjects |
US13/453,540 | 2012-04-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508477A Division JP6254937B2 (ja) | 2011-04-27 | 2012-04-24 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020070727A Division JP7311114B2 (ja) | 2011-04-27 | 2020-04-10 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018030860A true JP2018030860A (ja) | 2018-03-01 |
JP2018030860A5 JP2018030860A5 (ja) | 2018-04-12 |
Family
ID=47068083
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508477A Active JP6254937B2 (ja) | 2011-04-27 | 2012-04-24 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
JP2017179578A Pending JP2018030860A (ja) | 2011-04-27 | 2017-09-19 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
JP2020070727A Active JP7311114B2 (ja) | 2011-04-27 | 2020-04-10 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508477A Active JP6254937B2 (ja) | 2011-04-27 | 2012-04-24 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020070727A Active JP7311114B2 (ja) | 2011-04-27 | 2020-04-10 | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120276208A1 (ja) |
EP (1) | EP2701711B1 (ja) |
JP (3) | JP6254937B2 (ja) |
KR (5) | KR20160043140A (ja) |
AU (2) | AU2012249967A1 (ja) |
CA (1) | CA2834042C (ja) |
ES (1) | ES2833081T3 (ja) |
MX (1) | MX2013012449A (ja) |
PE (2) | PE20140869A1 (ja) |
SG (2) | SG10201913704RA (ja) |
UA (1) | UA112433C2 (ja) |
WO (1) | WO2012148887A2 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120276208A1 (en) * | 2011-04-27 | 2012-11-01 | University Of South Australia | Acute cognitive and mood effects of plant polysaccharides in adult human subjects |
GB201305708D0 (en) | 2013-03-28 | 2013-05-15 | Clasado Inc | Novel use |
US20180256616A1 (en) * | 2015-07-31 | 2018-09-13 | Sivanaray, Inc. | Compounds, Compositions and Methods for Prevention or Treatment of Liver and Lipid-Related Conditions |
MX2019000881A (es) | 2016-07-28 | 2019-07-01 | Fonterra Cooperative Group Ltd | Producto lacteo y proceso. |
EP3568139A4 (en) * | 2017-01-13 | 2020-10-28 | Sivanaray, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR THE PREVENTION OR TREATMENT OF LIVER AND LIPID RELATED DISEASES |
WO2018156513A1 (en) * | 2017-02-21 | 2018-08-30 | Sivanaray Inc. | Compounds, compositions and methods for prevention or treatment of liver, lipid, and glucose-related conditions |
US20210161926A1 (en) * | 2018-08-08 | 2021-06-03 | Neuro Biofuels Limited | Methods for Treatment of Brain Injury and Brain Dysfunction |
KR20230063881A (ko) | 2021-11-02 | 2023-05-09 | 주식회사 엘지에너지솔루션 | 전력저장원 관리장치 및 그 제어 방법 |
US11883457B1 (en) * | 2022-09-06 | 2024-01-30 | Optigenex Inc. | Method of enhancing cognition in individuals with at least normal cognition |
CN115317507A (zh) * | 2022-09-19 | 2022-11-11 | 中国科学院海洋研究所 | 低分子量褐藻多糖硫酸酯在制备抗多动症药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6254937B2 (ja) * | 2011-04-27 | 2017-12-27 | マナテク・インコーポレーテツド | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL331541A1 (en) * | 1996-08-09 | 1999-07-19 | Mannatech | Compositions of plant carbohydrates used as alimentary additives |
US6929807B1 (en) | 1996-08-09 | 2005-08-16 | Mannatech, Inc. | Compositions of plant carbohydrates as dietary supplements |
-
2012
- 2012-04-23 US US13/453,540 patent/US20120276208A1/en not_active Abandoned
- 2012-04-24 ES ES12776559T patent/ES2833081T3/es active Active
- 2012-04-24 AU AU2012249967A patent/AU2012249967A1/en not_active Abandoned
- 2012-04-24 KR KR1020167008979A patent/KR20160043140A/ko active Application Filing
- 2012-04-24 PE PE2013002406A patent/PE20140869A1/es not_active Application Discontinuation
- 2012-04-24 KR KR1020197013846A patent/KR20190055268A/ko not_active IP Right Cessation
- 2012-04-24 MX MX2013012449A patent/MX2013012449A/es active IP Right Grant
- 2012-04-24 KR KR1020217038790A patent/KR102516683B1/ko active IP Right Grant
- 2012-04-24 CA CA2834042A patent/CA2834042C/en active Active
- 2012-04-24 JP JP2014508477A patent/JP6254937B2/ja active Active
- 2012-04-24 SG SG10201913704RA patent/SG10201913704RA/en unknown
- 2012-04-24 UA UAA201312473A patent/UA112433C2/uk unknown
- 2012-04-24 KR KR1020187017974A patent/KR20180073718A/ko active Application Filing
- 2012-04-24 EP EP12776559.2A patent/EP2701711B1/en active Active
- 2012-04-24 PE PE2018000279A patent/PE20181047A1/es unknown
- 2012-04-24 KR KR1020137031566A patent/KR20140041503A/ko active Application Filing
- 2012-04-24 WO PCT/US2012/034752 patent/WO2012148887A2/en active Application Filing
- 2012-04-24 SG SG2013078951A patent/SG194608A1/en unknown
-
2016
- 2016-03-21 AU AU2016201764A patent/AU2016201764A1/en not_active Abandoned
-
2017
- 2017-09-19 JP JP2017179578A patent/JP2018030860A/ja active Pending
-
2020
- 2020-04-10 JP JP2020070727A patent/JP7311114B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6254937B2 (ja) * | 2011-04-27 | 2017-12-27 | マナテク・インコーポレーテツド | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 |
Non-Patent Citations (1)
Title |
---|
BEST, T. ET AL., DEV. NEUROPSYCHOL., 2010, VOL. 35, NO.1, P.66-80, JPN6015006339 * |
Also Published As
Publication number | Publication date |
---|---|
KR20190055268A (ko) | 2019-05-22 |
KR20160043140A (ko) | 2016-04-20 |
AU2016201764A1 (en) | 2016-04-07 |
SG10201913704RA (en) | 2020-03-30 |
WO2012148887A2 (en) | 2012-11-01 |
JP2014522389A (ja) | 2014-09-04 |
KR102516683B1 (ko) | 2023-04-03 |
UA112433C2 (uk) | 2016-09-12 |
US20120276208A1 (en) | 2012-11-01 |
KR20180073718A (ko) | 2018-07-02 |
EP2701711A2 (en) | 2014-03-05 |
NZ616789A (en) | 2016-05-27 |
KR20140041503A (ko) | 2014-04-04 |
PE20181047A1 (es) | 2018-07-03 |
EP2701711B1 (en) | 2020-09-30 |
JP2020125312A (ja) | 2020-08-20 |
JP7311114B2 (ja) | 2023-07-19 |
WO2012148887A9 (en) | 2012-12-27 |
ES2833081T3 (es) | 2021-06-14 |
JP6254937B2 (ja) | 2017-12-27 |
KR20210149215A (ko) | 2021-12-08 |
SG194608A1 (en) | 2013-12-30 |
CA2834042C (en) | 2018-12-11 |
CA2834042A1 (en) | 2012-11-01 |
MX2013012449A (es) | 2014-04-16 |
AU2012249967A1 (en) | 2013-11-07 |
EP2701711A4 (en) | 2014-11-05 |
PE20140869A1 (es) | 2014-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7311114B2 (ja) | 成人対象における認知及び気分に対する植物ポリサッカライドの急性効果 | |
Makino et al. | Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 | |
Ossoukhova et al. | Improved working memory performance following administration of a single dose of American ginseng (Panax quinquefolius L.) to healthy middle‐age adults | |
Lim et al. | Supplementation with Aspergillus oryzae-fermented kochujang lowers serum cholesterol in subjects with hyperlipidemia | |
Keylock et al. | Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly | |
Khorshidi-Hosseini et al. | Effect of glutamine and maltodextrin acute supplementation on anaerobic power | |
Best et al. | Acute effects of a dietary non-starch polysaccharide supplement on cognitive performance in healthy middle-aged adults | |
Green et al. | Placebo expectancy effects in the relationship between glucose and cognition | |
Petrelli et al. | Mental and physical effects of energy drinks consumption in an Italian young people group: a pilot study | |
Warkentin et al. | Associations of appetitive behaviors in 7-year-old children with their cardiometabolic health at 10 years of age | |
Tsuchiya et al. | Safety evaluation of the excessive intake of ceramide-containing acetic acid bacteria-a randomized, double-blind, placebo-controlled study over a 4-week period | |
Mathew H et al. | Attention and reaction time in university students following the consumption of red bull® | |
WO2024034424A1 (ja) | やる気増加用組成物 | |
Mobarakeh et al. | The association between diet quality and anxiety among young couples in shiraz: a cross-sectional study | |
NZ705719B2 (en) | Acute cognitive and mood effects of plant polysaccharides in adult human subjects | |
Nishihira et al. | Amelioration of bowel movement by daily ingestion of Kumaizasa (Sasa. senanensis) powder: A placebo-controlled, randomized, double-blind, parallel-group comparison study | |
Silver et al. | Dark chocolate (70% Cacao) modulates gamma wave frequencies in vigorously active individuals | |
NZ705719A (en) | Acute cognitive and mood effects of plant polysaccharides in adult human subjects | |
NZ616789B2 (en) | Acute cognitive and mood effects of plant polysaccharides in adult human subjects | |
Mohammadkhani et al. | Relationship between consumption of different food groups, diet quality index, and anthropometric indices with acne in adolescents | |
Widyasari et al. | Vegetables Consumption Before Carbohydrates Improves Daily Fiber Intake and Blood Sugar Levels in Patients With Type 2 Diabetes Mellitus | |
Jun et al. | Association between plant protein intake and grip strength in Koreans aged 50 years or older: Korea National Health and Nutrition Examination Survey 2016–2018 | |
Taherkhani et al. | The effect of 8 weeks aerobic training and consuming green tea on Lipid Profile and the blood sugar of overweight men | |
JP5875213B2 (ja) | 生姜抽出物とl−カルニチンとを含有する組成物 | |
Papandreou | Associations between mean oxygen saturation and thiobarbituric acid reacting substances after an intervention program in obstructive sleep apnoea syndrome patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171013 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190718 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191210 |